Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination with Chemotherapy in KRAS G12D–Mutated Pancreatic Cancer Models
European Journal of Cancer · 2026-11 · 248 · 117697
DOI: 10.1016/j.ejca.2026.117697 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von J. Teh und 5 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Teh, J., Kuhlberg, C., Cadelina, G., Pizzano, J., Masson, E., & Wang, X. (2026). Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination with Chemotherapy in KRAS G12D–Mutated Pancreatic Cancer Models. European Journal of Cancer, 248, 117697. https://doi.org/10.1016/j.ejca.2026.117697
Vancouver
Teh J, Kuhlberg C, Cadelina G, Pizzano J, Masson E, Wang X. Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination with Chemotherapy in KRAS G12D–Mutated Pancreatic Cancer Models. European Journal of Cancer. 2026;248:117697. doi:10.1016/j.ejca.2026.117697
BibTeX
@article{Teh2026,
author = {Teh, J. and Kuhlberg, C. and Cadelina, G. and Pizzano, J. and Masson, E. and Wang, X.},
title = {Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination with Chemotherapy in KRAS G12D–Mutated Pancreatic Cancer Models},
journal = {European Journal of Cancer},
year = {2026},
volume = {248},
pages = {117697},
doi = {10.1016/j.ejca.2026.117697}
}
EUVIMED